Evidence map›Paper›PMID 37850654›Full record

ArticleCNS neuroscience & therapeutics2024

Eomesodermin expression in CD4

Sheng Chen, Xiao Huan, Chun-Zuan Xu, Su-Shan Luo, Chong-Bo Zhao, Hua-Hua Zhong, Xue-Ying Zheng, Kai Qiao, Yi Dong, Ying Wang and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in CNS neuroscience & therapeutics, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
1.2field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Eomesodermin expression in CD4CNS neuroscience & therapeutics · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Sheng ChenDepartment of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.ORCID 0000-0002-7934-015X
Xiao HuanHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Chun-Zuan XuDepartment of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Su-Shan LuoHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.ORCID 0000-0002-9033-7568
Chong-Bo ZhaoHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.ORCID 0000-0001-9481-1418
Hua-Hua ZhongHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Xue-Ying ZhengDepartment of Biostatistics, School of Public Health and Key Laboratory of Public Health Safety, Fudan University, Shanghai, China.
Kai QiaoHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Yi DongHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.ORCID 0000-0001-6630-112X
Ying WangDepartment of Pharmacy, Fudan University Huashan Hospital, Shanghai, China.
Chang-Yun LiuDepartment of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Hua-Pin HuangDepartment of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.
Yan ChenHuashan Rare Disease Center and Department of Neurology, Huashan Hospital, Shanghai Medical College, National Center for Neurological Disorders, Fudan University, Shanghai, China.
Zhang-Yu ZouDepartment of Neurology, Fujian Medical University Union Hospital, Fuzhou, China.ORCID 0000-0002-8277-1110
Fudan University · CNFujian Medical University · CN

Funding

National Natural Science Foundation of China 81901286, 81974199, 82271458The Joint Funds for the innovation of science and Technology, Fujian province 2018Y9026, 2021Y9065The Startup Fund for scientific research, Fujian Medical University 2018QH1032
6 · The paper itself

Abstract

aimTo clarify the role of Eomesodermin (EOMES) to serve as a disease-relevant biomarker and the intracellular molecules underlying the immunophenotype shifting of CD4

methodsThe derivation and validation cohorts included a total of 148 ALS patients and 101 healthy controls (HCs). Clinical data and peripheral blood were collected. T-cell subsets and the EOMES expression were quantified using multicolor flow cytometry. Serum neurofilament light chain (NFL) was measured. In 1-year longitudinal follow-ups, the ALSFRS-R scores and primary endpoint events were further recorded in the ALS patients of the validation cohort.

resultsIn the derivation cohort, the CD4

conclusionsWe demonstrated that increased CD4

Indexed as

Amyotrophic Lateral SclerosisCD4-Positive T-LymphocytesT-Box Domain ProteinsBiomarkersDisease ProgressionHumansLongitudinal StudiesPrognosisT-LymphocytesBiomarkersEOMES protein, humanT-Box Domain Proteinsamyotrophic lateral sclerosisbulbar onsetCD4+T lymphocyteCXCR3eomesoderminneurofilament light chainprognosis

Identifiers

PMID37850654
PMCPMC11017423
OpenAlexW4387728843

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.